The following is a summary of the NovaBay Pharmaceuticals, Inc. (NBY) Q4 2023 Earnings Call Transcript:
Financial Performance:
NovaBay reported a total Q4 2023 sales net of $3.7 million, marking a 2% increase from the previous year.
The gross margin on net product revenue for the quarter was 49%, slightly higher than the 48% of Q4 2022.
The company's net loss for Q4 2023 amounted to $9.2 million, or $1.33 per share.
For the whole of 2023, total sales net were $14.7 million, and cash and cash equivalents stood at $3.1 million at year end.
Business Progress:
NovaBay sold its skincare business DERMAdoctor, choosing to focus solely on its core eye care business.
The company saw a significant rise in subscription-based unit sales of Avenova Spray.
Launched two promotional programs for Avenova branded products, and extended its reach via a new co-marketing agreement with Eyenovia for the distribution of FDA-approved ophthalmic steroid, Clobetasol.
More details: NovaBay Pharmaceuticals IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.